301 related articles for article (PubMed ID: 2844392)
21. Cell-cycle associated transcriptional regulation of ribonucleotide reductase in L1210 leukemia cells and drug-resistant variants.
Johnson CE; Hughes K; Cory JG
Cancer Commun; 1991; 3(10-11):341-9. PubMed ID: 1760249
[TBL] [Abstract][Full Text] [Related]
22. 2'-Deoxy-2'-methylene derivatives of adenosine, guanosine, tubercidin, cytidine and uridine as inhibitors of L1210 cell growth in culture.
Cory AH; Samano V; Robins MJ; Cory JG
Biochem Pharmacol; 1994 Jan; 47(2):365-71. PubMed ID: 8304981
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of drug resistance to inhibitors directed at the individual subunits of ribonucleotide reductase.
Carter GL; Thompson DP; Cory JG
Cancer Commun; 1989; 1(1):13-20. PubMed ID: 2701080
[TBL] [Abstract][Full Text] [Related]
24. Altered efflux properties of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory JG; Cory AH; Lorico A; Rappa G; Sartorelli AC
Anticancer Res; 1997; 17(5A):3185-93. PubMed ID: 9413147
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells.
Chitambar CR; Narasimhan J; Guy J; Sem DS; O'Brien WJ
Cancer Res; 1991 Nov; 51(22):6199-201. PubMed ID: 1933878
[TBL] [Abstract][Full Text] [Related]
26. Quantification of ribonucleotide reductase expression in wild-type and hydroxyurea-resistant cell lines employing in situ reverse transcriptase polymerase chain reaction and a computerized image analysis system.
Wadler S; Zhang H; Cammer M; Hu XP
Anal Biochem; 1999 Feb; 267(1):24-9. PubMed ID: 9918651
[TBL] [Abstract][Full Text] [Related]
27. Ribonucleotide reductase activity and growth of glutathione-depleted mouse leukemia L1210 cells in vitro.
Weckbecker G; Cory JG
Cancer Lett; 1988 Jun; 40(3):257-64. PubMed ID: 3289734
[TBL] [Abstract][Full Text] [Related]
28. Development of resistance to hydroxyurea during treatment of human myelogenous leukemia K562 cells with alpha-difluoromethylornithine as a result of coamplification of genes for ornithine decarboxylase and ribonucleotide reductase R2 subunit.
Ask A; Persson L; Rehnholm A; Frostesjö L; Holm I; Heby O
Cancer Res; 1993 Nov; 53(21):5262-8. PubMed ID: 8221660
[TBL] [Abstract][Full Text] [Related]
29. Studies on the differential mechanisms of inhibition of ribonucleotide reductase by specific inhibitors of the non-heme iron subunit.
Sato A; Bacon PE; Cory JG
Adv Enzyme Regul; 1984; 22():231-41. PubMed ID: 6089512
[TBL] [Abstract][Full Text] [Related]
30. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
Jackman AL; Alison DL; Calvert AH; Harrap KR
Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
[TBL] [Abstract][Full Text] [Related]
31. Substituted 2-acylpyridine-alpha-(N)-hetarylhydrazones as inhibitors of ribonucleotide reductase activity and L1210 cell growth.
Cory JG; Downes DL; Cory AH; Schaper KJ; Seydel JK
Anticancer Res; 1994; 14(3A):875-9. PubMed ID: 8074487
[TBL] [Abstract][Full Text] [Related]
32. Differential turnover of the subunits of ribonucleotide reductase in synchronized leukemia L1210 cells.
Rubin EH; Cory JG
Cancer Res; 1986 Dec; 46(12 Pt 1):6165-8. PubMed ID: 3536076
[TBL] [Abstract][Full Text] [Related]
33. Effect of ribonucleotide reductase inhibitors on the growth of human colon carcinoma HT-29 cells in culture.
Matsumoto M; Tihan T; Cory JG
Cancer Chemother Pharmacol; 1990; 26(5):323-9. PubMed ID: 2208572
[TBL] [Abstract][Full Text] [Related]
34. Selection and characterization of mutant S49 T-lymphoma cell lines resistant to phosphonoformic acid: evidence for inhibition of ribonucleotide reductase.
Albert DA; Gudas LJ
J Cell Physiol; 1986 May; 127(2):281-7. PubMed ID: 2939095
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
Nandy P; Lien EJ; Avramis VI
Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives.
Matsumoto M; Fox JG; Wang PH; Koneru PB; Lien EJ; Cory JG
Biochem Pharmacol; 1990 Oct; 40(8):1779-83. PubMed ID: 2242014
[TBL] [Abstract][Full Text] [Related]
37. Selection of 9-beta-D-arabinofuranosyladenine-resistant human T-lymphoblasts with altered ribonucleotide reductase activity.
Fridland A
Cancer Res; 1984 Oct; 44(10):4328-32. PubMed ID: 6380707
[TBL] [Abstract][Full Text] [Related]
38. Mouse leukemia L1210 cells selected for resistance to the ribonucleotide reductase inhibitor, 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone show altered response to DNA damaging agents.
Crenshaw TR; Cory JG
Int J Oncol; 1999 Sep; 15(3):487-90. PubMed ID: 10427129
[TBL] [Abstract][Full Text] [Related]
39. Deoxyadenosine toxicity and cell cycle arrest in hydroxyurea-resistant S49 T-lymphoma cells.
Albert DA; Nodzenski E
Exp Cell Res; 1988 Dec; 179(2):417-28. PubMed ID: 3056732
[TBL] [Abstract][Full Text] [Related]
40. Hydroxyurea-induced conversion of mammalian ribonucleotide reductase to a form hypersensitive to bleomycin.
McClarty GA; Chan AK; Wright JA
Cancer Res; 1986 Sep; 46(9):4516-21. PubMed ID: 2425956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
